Clinical Trials
10
Trial Phases
4 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Theravia
- Target Recruit Count
- 50
- Registration Number
- NCT06578507
- Locations
- 🇫🇷
GHEF- Site de Marne-la-Vallée, Jossigny, France
🇫🇷Institut d'Hématologie et d'oncologie pédiatrique - IHOPe, Lyon, France
🇫🇷Centre Hospitalier Intercommunal Créteil, Créteil, France
Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Theravia
- Target Recruit Count
- 33
- Registration Number
- NCT05470270
- Locations
- 🇫🇷
InterCommunal Hospital Centre of Creteil, Créteil, France
🇫🇷Necker University Hospital, Paris, France
🇫🇷Robert Debré Hospital, Paris, France
A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Theravia
- Target Recruit Count
- 28
- Registration Number
- NCT05025072
- Locations
- 🇬🇧
Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, United Kingdom
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Theravia
- Target Recruit Count
- 2093
- Registration Number
- NCT04707235
- Locations
- 🇫🇷
Amiens - Picardie Hospital Adults, Amiens, France
🇫🇷Amiens Picardie Hospital Children, Amiens, France
🇫🇷Clinique de l'Europe Amiens, Amiens, France
SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Theravia
- Target Recruit Count
- 86
- Registration Number
- NCT03806452
- Locations
- 🇨🇮
Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS), Abidjan, Côte D'Ivoire
🇫🇷CHU d'Angers, Angers, France
🇫🇷Hôpital Saint-André, Bordeaux, France
- Prev
- 1
- 2
- Next
News
Norgine Expands Rare Disease Portfolio with Strategic Acquisition of Theravia
Norgine has entered a definitive agreement to acquire Theravia from Mérieux Equity Partners, adding key rare disease treatments SIKLOS® for sickle cell disease and ORPHACOL® for genetic bile disorders to its portfolio.